Zhejiang Orient Gene Biotech Co Ltd (688298) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.52 Million ≈ $-4.47 Million USD) by net assets (CN¥6.49 Billion ≈ $950.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zhejiang Orient Gene Biotech Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Zhejiang Orient Gene Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pareto Bank ASA
OL:PARB
|
-0.015x |
|
China Railway Harbin Group of Technology Corp. A
SHG:688459
|
N/A |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
N/A |
|
FinVolution Group
F:PP3
|
0.028x |
|
Canadian Banc Corp
TO:BK
|
0.022x |
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
0.020x |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
-0.003x |
|
Indointernet Tbk PT
JK:EDGE
|
0.095x |
Annual Cash Flow Conversion Efficiency for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Orient Gene Biotech Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.79 Billion ≈ $993.80 Million |
CN¥-348.33 Million ≈ $-50.97 Million |
-0.051x | +75.83% |
| 2023-12-31 | CN¥7.55 Billion ≈ $1.10 Billion |
CN¥-1.60 Billion ≈ $-234.43 Million |
-0.212x | -158.95% |
| 2022-12-31 | CN¥8.32 Billion ≈ $1.22 Billion |
CN¥3.00 Billion ≈ $438.40 Million |
0.360x | -52.35% |
| 2021-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
CN¥5.20 Billion ≈ $761.49 Million |
0.755x | +3.44% |
| 2020-12-31 | CN¥2.45 Billion ≈ $358.72 Million |
CN¥1.79 Billion ≈ $261.98 Million |
0.730x | +242.35% |
| 2019-12-31 | CN¥254.13 Million ≈ $37.19 Million |
CN¥54.21 Million ≈ $7.93 Million |
0.213x | +0.12% |
| 2018-12-31 | CN¥208.03 Million ≈ $30.44 Million |
CN¥44.33 Million ≈ $6.49 Million |
0.213x | -12.27% |
| 2017-12-31 | CN¥138.12 Million ≈ $20.21 Million |
CN¥33.54 Million ≈ $4.91 Million |
0.243x | +103.04% |
| 2016-12-31 | CN¥98.72 Million ≈ $14.45 Million |
CN¥11.81 Million ≈ $1.73 Million |
0.120x | -- |
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more